SUPERFIN FORMOTEROLFORMULERING

A pharmaceutical aerosol formulation to be administered by a pressurized metered dose inhaler comprising as active ingredients formoterol fumarate in a concentration comprised between 0.003 and 0.192% w/v and beclometasone dipropionate, in a solution of a liquefied hydrofluoroalkane (HFA) propellant...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	FERRARIS, Alessandra, DAVIES, Rebecca Jaine, BRAMBILLA, Gaetano, CHURCH, Tanya Kathleen, GANDERTON, David, MEAKIN, Brian John, LEWIS, David Andrew
Format:	Patent
Sprache:	dan
Schlagworte:	CHEMISTRY HETEROCYCLIC COMPOUNDS HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

container_end_page
container_issue
container_start_page
container_title
container_volume
creator	FERRARIS, Alessandra DAVIES, Rebecca Jaine BRAMBILLA, Gaetano CHURCH, Tanya Kathleen GANDERTON, David MEAKIN, Brian John LEWIS, David Andrew
description	A pharmaceutical aerosol formulation to be administered by a pressurized metered dose inhaler comprising as active ingredients formoterol fumarate in a concentration comprised between 0.003 and 0.192% w/v and beclometasone dipropionate, in a solution of a liquefied hydrofluoroalkane (HFA) propellant, ethanol in anhydrous form as co-solvent, in a concentration comprised between 10% and 20% w/w, and hydrochloric acid, in a concentration such that the apparent pH range of the formulation is between 2.5 and 5.0, wherein the amount of residual water is less than 1500 ppm on the total weight of the formulation, and wherein the fraction of particles equal or less than 1.1 µm delivered on actuation of the inhaler is at least 30%, for use in the treatment of a respiratory disorder.
format	Patent
fullrecord	<record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_DK3494995TT3</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>DK3494995TT3</sourcerecordid><originalsourceid>FETCH-epo_espacenet_DK3494995TT33</originalsourceid><addsrcrecordid>eNrjZJALDg1wDXLz9FNw8w_y9Q9xDfL3AbFCfVyDPP3ceRhY0xJzilN5oTQ3g6Kba4izh25qQX58anFBYnJqXmpJvIu3sYmliaWlaUiIsTExagD3hiJq</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>SUPERFIN FORMOTEROLFORMULERING</title><source>esp@cenet</source><creator>FERRARIS, Alessandra ; DAVIES, Rebecca Jaine ; BRAMBILLA, Gaetano ; CHURCH, Tanya Kathleen ; GANDERTON, David ; MEAKIN, Brian John ; LEWIS, David Andrew</creator><creatorcontrib>FERRARIS, Alessandra ; DAVIES, Rebecca Jaine ; BRAMBILLA, Gaetano ; CHURCH, Tanya Kathleen ; GANDERTON, David ; MEAKIN, Brian John ; LEWIS, David Andrew</creatorcontrib><description>A pharmaceutical aerosol formulation to be administered by a pressurized metered dose inhaler comprising as active ingredients formoterol fumarate in a concentration comprised between 0.003 and 0.192% w/v and beclometasone dipropionate, in a solution of a liquefied hydrofluoroalkane (HFA) propellant, ethanol in anhydrous form as co-solvent, in a concentration comprised between 10% and 20% w/w, and hydrochloric acid, in a concentration such that the apparent pH range of the formulation is between 2.5 and 5.0, wherein the amount of residual water is less than 1500 ppm on the total weight of the formulation, and wherein the fraction of particles equal or less than 1.1 µm delivered on actuation of the inhaler is at least 30%, for use in the treatment of a respiratory disorder.</description><language>dan</language><subject>CHEMISTRY ; HETEROCYCLIC COMPOUNDS ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; ORGANIC CHEMISTRY ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2020</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20200323&DB=EPODOC&CC=DK&NR=3494995T3$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25564,76547</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20200323&DB=EPODOC&CC=DK&NR=3494995T3$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>FERRARIS, Alessandra</creatorcontrib><creatorcontrib>DAVIES, Rebecca Jaine</creatorcontrib><creatorcontrib>BRAMBILLA, Gaetano</creatorcontrib><creatorcontrib>CHURCH, Tanya Kathleen</creatorcontrib><creatorcontrib>GANDERTON, David</creatorcontrib><creatorcontrib>MEAKIN, Brian John</creatorcontrib><creatorcontrib>LEWIS, David Andrew</creatorcontrib><title>SUPERFIN FORMOTEROLFORMULERING</title><description>A pharmaceutical aerosol formulation to be administered by a pressurized metered dose inhaler comprising as active ingredients formoterol fumarate in a concentration comprised between 0.003 and 0.192% w/v and beclometasone dipropionate, in a solution of a liquefied hydrofluoroalkane (HFA) propellant, ethanol in anhydrous form as co-solvent, in a concentration comprised between 10% and 20% w/w, and hydrochloric acid, in a concentration such that the apparent pH range of the formulation is between 2.5 and 5.0, wherein the amount of residual water is less than 1500 ppm on the total weight of the formulation, and wherein the fraction of particles equal or less than 1.1 µm delivered on actuation of the inhaler is at least 30%, for use in the treatment of a respiratory disorder.</description><subject>CHEMISTRY</subject><subject>HETEROCYCLIC COMPOUNDS</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2020</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZJALDg1wDXLz9FNw8w_y9Q9xDfL3AbFCfVyDPP3ceRhY0xJzilN5oTQ3g6Kba4izh25qQX58anFBYnJqXmpJvIu3sYmliaWlaUiIsTExagD3hiJq</recordid><startdate>20200323</startdate><enddate>20200323</enddate><creator>FERRARIS, Alessandra</creator><creator>DAVIES, Rebecca Jaine</creator><creator>BRAMBILLA, Gaetano</creator><creator>CHURCH, Tanya Kathleen</creator><creator>GANDERTON, David</creator><creator>MEAKIN, Brian John</creator><creator>LEWIS, David Andrew</creator><scope>EVB</scope></search><sort><creationdate>20200323</creationdate><title>SUPERFIN FORMOTEROLFORMULERING</title><author>FERRARIS, Alessandra ; DAVIES, Rebecca Jaine ; BRAMBILLA, Gaetano ; CHURCH, Tanya Kathleen ; GANDERTON, David ; MEAKIN, Brian John ; LEWIS, David Andrew</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_DK3494995TT33</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>dan</language><creationdate>2020</creationdate><topic>CHEMISTRY</topic><topic>HETEROCYCLIC COMPOUNDS</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>FERRARIS, Alessandra</creatorcontrib><creatorcontrib>DAVIES, Rebecca Jaine</creatorcontrib><creatorcontrib>BRAMBILLA, Gaetano</creatorcontrib><creatorcontrib>CHURCH, Tanya Kathleen</creatorcontrib><creatorcontrib>GANDERTON, David</creatorcontrib><creatorcontrib>MEAKIN, Brian John</creatorcontrib><creatorcontrib>LEWIS, David Andrew</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>FERRARIS, Alessandra</au><au>DAVIES, Rebecca Jaine</au><au>BRAMBILLA, Gaetano</au><au>CHURCH, Tanya Kathleen</au><au>GANDERTON, David</au><au>MEAKIN, Brian John</au><au>LEWIS, David Andrew</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>SUPERFIN FORMOTEROLFORMULERING</title><date>2020-03-23</date><risdate>2020</risdate><abstract>A pharmaceutical aerosol formulation to be administered by a pressurized metered dose inhaler comprising as active ingredients formoterol fumarate in a concentration comprised between 0.003 and 0.192% w/v and beclometasone dipropionate, in a solution of a liquefied hydrofluoroalkane (HFA) propellant, ethanol in anhydrous form as co-solvent, in a concentration comprised between 10% and 20% w/w, and hydrochloric acid, in a concentration such that the apparent pH range of the formulation is between 2.5 and 5.0, wherein the amount of residual water is less than 1500 ppm on the total weight of the formulation, and wherein the fraction of particles equal or less than 1.1 µm delivered on actuation of the inhaler is at least 30%, for use in the treatment of a respiratory disorder.</abstract><oa>free_for_read</oa></addata></record>
fulltext	fulltext_linktorsrc
identifier
ispartof
issn
language	dan
recordid	cdi_epo_espacenet_DK3494995TT3
source	esp@cenet
subjects	CHEMISTRY HETEROCYCLIC COMPOUNDS HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
title	SUPERFIN FORMOTEROLFORMULERING
url	https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T06%3A57%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=FERRARIS,%20Alessandra&rft.date=2020-03-23&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EDK3494995TT3%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true